Skip to main content
main-content

medwireNews@ASCO 2017

20-06-2017 | Non-small cell lung cancer | Interview | Video

Lung cancer highlights from John Heymach

ASCO expert Dr John Heymach reviews the key lung cancer trial findings presented at the ASCO 2017 annual meeting.

21-06-2017 | Non-small cell lung cancer | Conference | News

Alectinib ‘new standard of care’ for untreated ALK-positive NSCLC

Compared with crizotinib, alectinib significantly improves progression-free survival in treatment-naïve patients with advanced non-small-cell lung cancer harboring an anaplastic lymphoma kinase rearrangement, shows the ALEX trial.

21-06-2017 | Non-small cell lung cancer | Conference | News

Dacomitinib improves EGFR-mutated NSCLC PFS over gefitinib, but at toxicity cost

The ARCHER 1050 investigators believe that their results establish dacomitinib as an addition to the first-line EGFR mutation-positive non-small-cell lung cancer treatment armamentarium, but caution that the associated toxicity needs to be managed.

Abiraterone acetate in prostate cancer

14-06-2017 | Prostate cancer | Conference | News

Upfront abiraterone supported in advanced prostate cancer

Administration of abiraterone acetate alongside first-line androgen deprivation therapy could be the new standard of care for men with locally advanced or metastatic prostate cancer, say the authors of two independent phase III trials.

16-06-2017 | Prostate cancer | Interview | Video

STAMPEDE trial changes standard of care

Presenting author Nicholas James discusses the STAMPEDE trial results supporting use of abiraterone acetate in advanced prostate cancer patients beginning long-term androgen deprivation therapy.

16-06-2017 | Prostate cancer | Interview | Video

LATITUDE supports first-line abiraterone use for metastatic prostate cancer

Study author Kim Chi explains the impact of the LATITUDE trial study findings for men with newly diagnosed metastatic prostate cancer.

Research news

30-06-2017 | Soft-tissue sarcoma | Conference | News

Immunotherapy shows promise in advanced sarcoma

Immunotherapy could have a role in the treatment of patients with certain sarcoma subtypes in the advanced disease setting, suggests research presented at the 2017 annual meeting of the American Society of Clinical Oncology. Here we provide a round-up of three studies investigating various immunotherapeutic strategies in advanced sarcoma patients.

29-06-2017 | Genetics | Conference | News

Routine detection of actionable mutations feasible, but benefit limited to a few

ProfiLER-01 study data suggest that high-throughput genomic testing can be incorporated into routine practice, but only a subset of patients derive a clinical benefit.

28-06-2017 | Renal cell carcinoma | Conference | News

Combining checkpoint blockade with targeted therapy in first-line advanced RCC

This report provides an overview of three studies investigating the combination of immunotherapy with targeted agents in treatment-naïve patients with locally advanced or metastatic renal cell carcinoma.

27-06-2017 | Pediatric and adolescent cancers | Conference | News

Steady decline in serious comorbidities among pediatric cancer survivors

Research presented at the 2017 annual meeting of the American Society of Clinical Oncology shows childhood cancer survivors diagnosed in more recent years can expect to experience fewer serious chronic conditions than those diagnosed in earlier decades.

26-06-2017 | Soft-tissue sarcoma | Conference | News

Aldoxorubicin has activity in advanced soft tissue sarcoma

The doxorubicin conjugate aldoxorubicin could be a suitable alternative to standard therapies for patients with relapsed or refractory soft tissue sarcoma, say researchers.

21-06-2017 | Non-small cell lung cancer | Conference | News

Dacomitinib improves EGFR-mutated NSCLC PFS over gefitinib, but at toxicity cost

The ARCHER 1050 investigators believe that their results establish dacomitinib as an addition to the first-line EGFR mutation-positive non-small-cell lung cancer treatment armamentarium, but caution that the associated toxicity needs to be managed.

21-06-2017 | Non-small cell lung cancer | Conference | News

Alectinib ‘new standard of care’ for untreated ALK-positive NSCLC

Compared with crizotinib, alectinib significantly improves progression-free survival in treatment-naïve patients with advanced non-small-cell lung cancer harboring an anaplastic lymphoma kinase rearrangement, shows the ALEX trial.

19-06-2017 | Lenvatinib | Conference | News

Lenvatinib equals sorafenib for unresectable HCC OS

REFLECT study findings indicate that lenvatinib offers non-inferior overall survival compared with the current standard of care, sorafenib, for the first-line treatment of patients with unresectable hepatocellular carcinoma.

14-06-2017 | Prostate cancer | Conference | News

Upfront abiraterone supported in advanced prostate cancer

Administration of abiraterone acetate alongside first-line androgen deprivation therapy could be the new standard of care for men with locally advanced or metastatic prostate cancer, say the authors of two independent phase III trials.

14-06-2017 | Urothelial cancer | Conference | News

First-line pembrolizumab feasible for cisplatin-ineligible advanced urothelial cancer patients

Advanced urothelial carcinoma patients who are unsuitable for platinum-based chemotherapy could benefit from first-line pembrolizumab, suggest phase II results reported at the American Society of Clinical Oncology 2017 annual meeting in Chicago, Illinois, USA.

14-06-2017 | Pediatric and adolescent cancers | Conference | News

Larotrectinib ‘potential standard of care’ for adult, pediatric TRK fusion tumors

Preliminary findings for larotrectinib suggest that the agent may offer an effective tumor type-agnostic treatment for adults and children presenting with tropomyosin receptor kinase fusions.

13-06-2017 | Urothelial cancer | Conference | News

Pembrolizumab after recurrence recommended for advanced urothelial carcinoma

A prespecified third analysis has confirmed initial findings of the KEYNOTE-045 trial of pembrolizumab in patients with advanced urothelial carcinoma who have progressed after platinum-based chemotherapy.

13-06-2017 | Non-small cell lung cancer | Conference | News

Pembrolizumab PFS2, OS results support first-line NSCLC strategy

Pembrolizumab offers better survival outcomes than platinum-doublet chemotherapy for treatment-naïve, non-small-cell lung cancer patients with a programmed cell death ligand 1 tumor proportion score of 50% or greater, the KEYNOTE-024 investigators say.

13-06-2017 | Melanoma | Conference | News

Nivolumab, ipilimumab duo elicits durable intracranial metastatic melanoma response

Patients with melanoma and untreated, asymptomatic brain metastases benefit from treatment with a combination of nivolumab and ipilimumab, suggest the results of the ABC and CheckMate 204 trials.

12-06-2017 | Patient-reported outcomes | Conference | News

Electronic PRO symptom monitoring benefits revealed

Using an electronic patient-reported outcomes system improves overall survival and offers other clinical benefits for patients undergoing chemotherapy for metastatic solid tumors, research suggests.

09-06-2017 | Non-small cell lung cancer | Conference | News

Atezolizumab–platinum-based chemotherapy NSCLC regimens advance to phase III trials

Results from a phase Ib study indicate that atezolizumab could be feasible in combination with one of three different platinum-doublet regimens for patients with stage IIIb–IV non-small-cell lung cancer without actionable genetic mutations.

08-06-2017 | Non-small cell lung cancer | ASCO 2017 | News

‘Encouraging’ results with post-progression atezolizumab in NSCLC

A post-hoc analysis of the OAK trial suggests that patients with advanced non-small-cell lung cancer who are performing well clinically at radiographic progression could benefit from continuation of treatment with atezolizumab.

06-06-2017 | Testicular cancer | Conference | News

Low testosterone risk flagged for testicular cancer survivors

Clinicians should be aware of the risk of hypogonadism in men who have been treated for testicular cancer, highlight findings from The Platinum Study.

06-06-2017 | Breast cancer | Conference | News

No increased risk of recurrence with pregnancy after breast cancer

Women with a history of early breast cancer can be reassured that becoming pregnant will not increase their risk of recurrence or death.

06-06-2017 | Human papillomavirus | Conference | News

HPV vaccination ‘tremendous potential’ for prevention of oral HPV infection

Routine vaccination against human papillomavirus has “tremendous potential” for reducing the risk of oral HPV infection and associated malignancy, suggests research presented at the 2017 American Society of Clinical Oncology annual meeting, held in Chicago, Illinois, USA.

Image Credits